MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium
Atlanta, Georgia 30329
February 21-22, 2018

AGENDA ITEM

Wednesday, February 21
8:00 Welcome & Introductions
     PURPOSE                  PRESIDER/PRESENTER(s)
     Dr. Nancy Bennett (ACIP Chair)
     Dr. Amanda Cohn (ACIP Executive Secretary; CDC)

8:30 Hepatitis Vaccines
     Introduction
     Review of GRADE (HEPLISAV-B)
     Considerations and proposed recommendations
     Public comment
     Vote
     Hepatitis A post-exposure prophylaxis GRADE
     Considerations and proposed recommendations
     Public comment
     Vote
     PURPOSE                  PRESIDER/PRESENTER(s)
     Information             Dr. Jose Romero (ACIP, WG Chair)
     & Discussion            Dr. Aaron Harris (CDC/NCHHSTP)
     Vote                    Dr. Sarah Schillie (CDC/NCHHSTP)
     Information             Dr. Sarah Schillie (CDC/NCHHSTP)
     & Discussion            Dr. Noele Nelson (CDC/NCHHSTP)
     Vote                    Dr. Noele Nelson (CDC/NCHHSTP)

10:15 Break
10:30 Influenza Vaccines
     Introduction
     Fluarix Quadrivalent: efficacy in children 6-35 months of age
     Surveillance update
     VE update
     Results of a randomized trial of a new H1N1 LAIV strain in US children
     Review of LAIV for 2 through 17 year olds
     Considerations and proposed recommendations
     Public comment
     Vote
     VFC Vote
     PURPOSE                  PRESIDER/PRESENTER(s)
     Information             Dr. Chip Walter (ACIP, WG Chair)
     & Discussion            Dr. Leonard Friedland (GSK)
     Vote                    Dr. Lynnette Brammer (CDC/NCIRD)
     Information             Dr. Brendan Flannery (CDC/NCIRD)
     & Discussion            Dr. Raburn Mallory (MedImmune/AstraZeneca)
     Vote                    Dr. Lisa Grohskopf (CDC/NCIRD), Dr. Jill Ferdinands (CDC/NCIRD)
     Vote                    Dr. Lisa Grohskopf (CDC/NCIRD)
     Vote                    Dr. Jeanne Santoli

12:45 Lunch
1:45 Evidence Based Recommendations
     Introduction
     Evidence to Recommendations Framework
     Public comment
     Vote
     PURPOSE                  PRESIDER/PRESENTER(s)
     Information             Dr. Grace Lee (ACIP, WG Chair)
     & Discussion            Dr. Wendy Carr (CDC/NCIRD)
     Vote                    Dr. Wendy Carr (CDC/NCIRD)

2:30 Anthrax
     Introduction
     Update on IM route of administration of vaccine
     Dose-sparing strategies when demand for vaccine excess
     Duration of antimicrobial component of PEP when used in combination with anthrax vaccine
     PURPOSE                  PRESIDER/PRESENTER(s)
     Information             Dr. David Stephens (ACIP, WG Chair)
     & Discussion            Dr. William Bower (CDC/NCEZID)
     Vote                    Dr. William Bower (CDC/NCEZID)

3:45 Break
4:00 Human Papillomavirus (HPV) Vaccines
     Introduction
     9-valent HPV vaccine safety data - VAERS update
     9-valent HPV vaccine rapid cycle analysis, Vaccine Safety Harmonization of upper age for male and female vaccination recommendations
     Trends in HPV-associated cancers in the United States
     Epidemiology of HPV infection in males
     PURPOSE                  PRESIDER/PRESENTER(s)
     Information             Dr. Peter Szilagyi (ACIP, WG Chair)
     & Discussion            Dr. Jorge Arana (CDC/NCEZID)
     Vote                    Dr. Jim Donahue (Marshfield Clinic)
     Information             Dr. Lauri Markowitz (CDC/NCIRD)
     & Discussion            Dr. Elizabeth Van Dyne, (CDC/NCCDPHP)
     Vote                    Dr. Anil Chaturvedi (NIH/NCI)

5:30 Public Comment
5:45 Adjourn
Thursday, February 22

8:00  Agency Updates & Unfinished Business
CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO
Information
Dr. Nancy Messonnier (CDC/NCIRD); Ex Officio Members

9:00  Pneumococcal
Introduction
PCV13 Effectiveness: Case Control Study
PCV13 Direct and Indirect Effects among Adults ≥65 Year Old
PCV13 effectiveness against pneumococcal pneumonia among U.S. Adults
Estimating Burden of Pneumococcal Pneumonia among Adults in the U.S. Progress of the research agenda to inform potential policy change
Information & Discussion
Dr. Grace Lee (ACIP, WG Chair)
Dr. Tamara Pilishvili (CDC/NCIRD)
Dr. John M. McLaughlin (Pfizer Vaccines)
Dr. Almea Matanock (CDC/NCIRD)

10:30  Vaccines and other biologics for prevention and treatment of healthcare-associated infections
Update
Information
Dr. Anthony Fiore (CDC/NCEZID)

11:00  Break

11:30  Meningococcal Disease
Introduction
Epidemiology of meningococcal disease among college students – United States, 2014-2016
Information & Discussion
Dr. David Stephens (ACIP, WG Chair)
Dr. Sarah Meyer (CDC/NCIRD)

12:00  Japanese Encephalitis (JE) Vaccine
Introduction
Review of JE and work group plans
Information & Discussion
Dr. Chip Walter (ACIP, WG Chair)
Dr. Susan Hills (CDC/NCEZID)

12:20  Public Comment

12:30  Adjourn

Acronyms
CDC  Centers for Disease Control & Prevention
CMS  Centers for Medicare and Medicaid Services
DoD  Department of Defense
DVA  Department of Veterans Affairs
FDA  Food and Drug Administration
GRADE  Grading of Recommendations Assessment, Development and Evaluation
HRSA  Health Resources and Services Administration
IHS  Indian Health Service
JE-VC  Vero cell culture-derived Japanese encephalitis
NCHHSTP  National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD  National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID  National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NCI  National Cancer Institute
NIH  National Institutes of Health
NVPO  National Vaccine Program Office
PCV13  13-valent pneumococcal conjugate vaccine
VFC  Vaccines for Children
WG  Work Group